Genmab ADR [GMAB] stock is trading at $28.84, down -1.20%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The GMAB shares have gain 0.59% over the last week, with a monthly amount drifted -11.91%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Genmab ADR [NASDAQ: GMAB] stock has seen the most recent analyst activity on September 23, 2025, when Guggenheim upgraded its rating to a Buy but kept the price target unchanged to $43 for it. Previously, Bernstein downgraded its rating to Underperform on April 01, 2025. On March 11, 2025, upgrade upgraded it’s rating to Outperform. Leerink Partners upgraded its rating to an Outperform but stick to its price target of $27 on February 13, 2025. Redburn Atlantic initiated its recommendation with a Buy. In a note dated August 20, 2024, JP Morgan downgraded a Neutral rating on this stock.
Genmab ADR [GMAB] stock has fluctuated between $17.24 and $33.65 over the past year. Currently, Wall Street analysts expect the stock to reach $41.25 within the next 12 months. Genmab ADR [NASDAQ: GMAB] shares were valued at $28.84 at the most recent close of the market. An investor can expect a potential return of 43.03% based on the average GMAB price forecast.
Analyzing the GMAB fundamentals
Genmab ADR [NASDAQ:GMAB] reported sales of 3.39B for the trailing twelve months, which represents a growth of 20.16%. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at 0.34%, Pretax Profit Margin comes in at 0.42%, and Net Profit Margin reading is 0.37%. To continue investigating profitability, this company’s Return on Assets is posted at 0.21, Equity is 0.25 and Total Capital is 0.21. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.21 points at the first support level, and at 27.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.41, and for the 2nd resistance point, it is at 29.98.
Ratios To Look Out For
For context, Genmab ADR’s Current Ratio is 6.22. In addition, the Quick Ratio stands at 6.20 and the Cash Ratio stands at 2.06. Considering the valuation of this stock, the price to sales ratio is 5.24, the price to book ratio is 3.35 and price to earnings (TTM) ratio is 14.40.
Transactions by insiders
Recent insider trading involved Klimovsky Judith V, Director, that happened on Jun 17 ’25 when 1300.0 shares were purchased.
